On the TA front, VIT back to re-test support - break this and low 20s incoming.The FA conundrum is that FY23 results will look good but is it deceiving?When your established competitors (EBO, API, SIG) are operating at 10% Gross Margin to VITs >30% then they're going to come for your lunch.At an annualised cost base of $20m (VIT had $10m below the line expenses for HY) it means $100m revenue is actually loss-making at 10% GM.GM at 10% requires revenue of $200m to B/E.So is it a value trap?
